• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

比较 WCK 5222（头孢吡肟-齐他培南）与联合抗菌治疗方案对耐碳青霉烯肠杆菌科细菌活性的研究

Comparative Evaluation of the Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant .

机构信息

Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.

Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA

出版信息

Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01669-19.

DOI:10.1128/AAC.01669-19
PMID:31844009
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7038276/
Abstract

The activity of WCK 5222 (cefepime-zidebactam) was compared to that of several available combination therapies among 30 clinical carbapenem-resistant (CRP) strains using gradient diffusion strips. The combinations included nonsusceptible β-lactams (cefepime, ceftolozane-tazobactam, and meropenem) with amikacin and fosfomycin. WCK 5222 MICs ranged from 2 to 32 mg/liter, and 97% were ≤16 mg/liter, while 105/146 (72%) combinations demonstrated inhibition below established susceptibility breakpoints. WCK 5222 monotherapy may be preferred over the combinations assessed for CRP infections.

摘要

采用梯度扩散条比较了 WCK 5222（头孢吡肟-齐他培南）与几种现有联合治疗方案在 30 株临床耐碳青霉烯肠杆菌科细菌（CRP）菌株中的活性。这些组合包括对β-内酰胺类（头孢吡肟、头孢他啶-阿维巴坦和美罗培南）耐药的药物与阿米卡星和磷霉素。WCK 5222 的 MIC 值范围为 2 至 32mg/L，97%≤16mg/L，而 105/146（72%）种组合的抑制作用低于既定的药敏折点。对于 CRP 感染，WCK 5222 单药治疗可能优于评估的联合治疗方案。

相似文献

1
Comparative Evaluation of the Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant .比较 WCK 5222（头孢吡肟-齐他培南）与联合抗菌治疗方案对耐碳青霉烯肠杆菌科细菌活性的研究
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01669-19.
2
Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.从一株耐碳青霉烯铜绿假单胞菌临床分离株中筛选出对 WCK 5222（头孢吡肟/齐他培南）耐药的突变株，并对其进行分子特征分析。
Microbiol Spectr. 2022 Feb 23;10(1):e0267821. doi: 10.1128/spectrum.02678-21.
3
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.WCK 5107（齐德巴坦）和WCK 5153是新型PBP2抑制剂，对铜绿假单胞菌表现出强大的“β-内酰胺增强剂”活性，包括产多重耐药金属β-内酰胺酶的高风险克隆株。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02529-16. Print 2017 Jun.
4
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.WCK 5222（头孢吡肟-齐地巴坦）对2015年全球收集的革兰氏阴性菌临床分离株的抗菌活性。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.00072-17. Print 2017 May.
5
Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.头孢吡肟/齐多夫定（WCK 5222）对纽约市医疗机构流行的肠杆菌科、铜绿假单胞菌和鲍曼不动杆菌的活性。
J Antimicrob Chemother. 2019 Oct 1;74(10):2938-2942. doi: 10.1093/jac/dkz294.
6
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.WCK 5222（头孢吡肟/齐地卡南）针对产生具有临床相关性β-内酰胺酶的革兰氏阴性菌的抗菌活性测试。
J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. doi: 10.1093/jac/dkx050.
7
Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.头孢吡肟、齐多夫定和联合制剂（WCK 5222）在中性粒细胞减少性肺炎小鼠模型中对耐多药铜绿假单胞菌的人模拟支气管肺部暴露的疗效。
J Antimicrob Chemother. 2020 Jan 1;75(1):149-155. doi: 10.1093/jac/dkz414.
8
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.耐碳青霉烯铜绿假单胞菌中磷霉素与非敏感性抗菌药物体外协同抗生素相互作用的流行率。
J Med Microbiol. 2019 Jun;68(6):893-897. doi: 10.1099/jmm.0.000984. Epub 2019 May 3.
9
Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant in the Neutropenic Murine Thigh Infection Model.WCK 5222（头孢吡肟-齐多夫定）对中性粒细胞减少症小鼠大腿感染模型中多药耐药菌的疗效。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00233-19. Print 2019 Jul.
10
Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems.WCK 5222（头孢吡肟-齐德巴坦）对全球收集的对碳青霉烯类不敏感的革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.01432-20.

引用本文的文献

1
Difficult-to-Treat Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal.重症患者难治性感染：综述与治疗建议
Antibiotics (Basel). 2025 Feb 11;14(2):178. doi: 10.3390/antibiotics14020178.
2
The Challenge of Treating Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria: A Narrative Review.治疗产金属β-内酰胺酶革兰氏阴性菌引起的感染面临的挑战：一篇叙述性综述
Drugs. 2024 Dec;84(12):1519-1539. doi: 10.1007/s40265-024-02102-8. Epub 2024 Oct 28.
3
Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia.成功使用头孢吡肟-齐多夫定（WCK 5222）作为挽救疗法治疗急性 T 细胞白血病成年患者广泛耐药新德里金属β-内酰胺酶产生铜绿假单胞菌感染的播散性感染。
Antimicrob Agents Chemother. 2023 Aug;67(8):e0050023. doi: 10.1128/aac.00500-23. Epub 2023 Jun 14.
4
New Drugs for the Treatment of Infections with Limited Treatment Options: A Narrative Review.治疗选择有限的感染的新药：叙述性综述
Antibiotics (Basel). 2022 Apr 26;11(5):579. doi: 10.3390/antibiotics11050579.
5
Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.从一株耐碳青霉烯铜绿假单胞菌临床分离株中筛选出对 WCK 5222（头孢吡肟/齐他培南）耐药的突变株，并对其进行分子特征分析。
Microbiol Spectr. 2022 Feb 23;10(1):e0267821. doi: 10.1128/spectrum.02678-21.
6
Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?虽败犹胜：落败的抗菌药物能否结成联盟对抗耐药病原体？
Antibiotics (Basel). 2021 May 28;10(6):646. doi: 10.3390/antibiotics10060646.
7
Structural Characterization of Diazabicyclooctane β-Lactam "Enhancers" in Complex with Penicillin-Binding Proteins PBP2 and PBP3 of Pseudomonas aeruginosa.与铜绿假单胞菌青霉素结合蛋白 PBP2 和 PBP3 复合物中二氮杂二环辛烷 β-内酰胺“增强剂”的结构特征。
mBio. 2021 Feb 16;12(1):e03058-20. doi: 10.1128/mBio.03058-20.
8
Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies.磷霉素作为全身感染管理的联合用药。对其体外和体内研究协同特性的系统评价。
Antibiotics (Basel). 2020 Aug 10;9(8):500. doi: 10.3390/antibiotics9080500.

本文引用的文献

1
Single β-lactams versus combinations as empiric therapy for infections with : assessing the susceptibility.单一β-内酰胺类药物与联合用药作为经验性治疗感染的比较：评估药敏性。
Infect Dis (Lond). 2020 Jan;52(1):33-38. doi: 10.1080/23744235.2019.1673900. Epub 2019 Oct 9.
2
Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant in the Neutropenic Murine Thigh Infection Model.WCK 5222（头孢吡肟-齐多夫定）对中性粒细胞减少症小鼠大腿感染模型中多药耐药菌的疗效。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00233-19. Print 2019 Jul.
3
Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.美罗培南/阿维巴坦耐药的铜绿假单胞菌临床分离株中 MexAB-OprM 过度表达及外排调节蛋白、青霉素结合蛋白和伴侣蛋白突变的联合作用。
J Antimicrob Chemother. 2019 Sep 1;74(9):2588-2595. doi: 10.1093/jac/dkz243.
4
A Combination Antibiogram Evaluation for in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals.美国医院 ICU 和非 ICU 环境下呼吸和血液来源的 联合抗生素药敏评价。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02564-18. Print 2019 Apr.
5
Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens.头孢吡肟-齐地巴坦对多重耐药革兰阴性病原菌的活性
Antibiotics (Basel). 2019 Mar 23;8(1):32. doi: 10.3390/antibiotics8010032.
6
Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gram-negative infections: A systematic review.体外抗生素协同活性对多重耐药革兰氏阴性感染的临床相关性：系统评价。
J Glob Antimicrob Resist. 2019 Jun;17:250-259. doi: 10.1016/j.jgar.2019.01.004. Epub 2019 Jan 15.
7
Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin.一名严重中性粒细胞减少患者的铜绿假单胞菌对头孢他啶/他唑巴坦高水平耐药机制及与妥布霉素协同治疗成功的案例
J Antimicrob Chemother. 2019 Jan 1;74(1):269-271. doi: 10.1093/jac/dky393.
8
Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory.临床实验室使用抗生素梯度扩散条进行常规协同试验的可行性。
J Antimicrob Chemother. 2018 Aug 1;73(8):2264-2265. doi: 10.1093/jac/dky165.
9
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.使用β-内酰胺酶抑制剂和β-内酰胺增强剂克服革兰氏阴性病原体耐药性的策略：三种新型二氮杂二环辛烷 WCK 5153、齐他培南（WCK 5107）和 WCK 4234 的活性。
J Med Chem. 2018 May 10;61(9):4067-4086. doi: 10.1021/acs.jmedchem.8b00091. Epub 2018 Apr 20.
10
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.WCK 5222（头孢吡肟/齐地卡南）针对产生具有临床相关性β-内酰胺酶的革兰氏阴性菌的抗菌活性测试。
J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. doi: 10.1093/jac/dkx050.